Join the Attention-Deficit Hyperactivity Disorder (ADHD) group to help and get support from people like you.
Attention-Deficit Hyperactivity Disorder (ADHD) News (Page 5)
Related terms: ADHD, Attention Deficit Disorder, Childhood hyperkinesis, ADD
FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)August 09, 2018 --Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”) a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) announc...
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
Lexington, Mass., USA – June 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved Mydayis (mixed salts of a single-entity amp...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product c...
Pfizer Receives FDA Approval for QuilliChew ER (methylphenidate hydrochloride) Extended-Release Chewable Tablets
Monday, December 7, 2015 - Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer now offers two different products for the...
Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) Once-Daily Liquid for ADHD in Children
MONMOUTH JUNCTION, N.J., October 20, 2015 – Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved Dyanavel XR (amphetamine), extended-release oral...
FDA Medwatch Alert: Daytrana Patch (methylphenidate transdermal system): Drug Safety Communication - Permanent Skin Color Changes
ISSUE: FDA is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit Hyperactivity Disorder (ADHD). FDA added a...
FDA Medwatch Alert: Methylphenidate ADHD Medications: Drug Safety Communication - Risk of Long-lasting Erections
ISSUE: FDA is warning that methylphenidate products (including Concerta, Daytrana, Focalin/Focalin XR, Metadate CD/Metadate ER, Methylin/Methylin ER, Quillivant XR, Ritalin/Ritalin LA/Ritalin SR),...
NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR for Once-Daily Treatment of ADHD
CUPERTINO, Calif., Oct. 1, 2012 /PRNewswire/ – NextWave Pharmaceuticals, an emerging specialty pharmaceutical company, announced FDA approval of Quillivant XR (methylphenidate hydrochloride) for...
FDA Medwatch Alert: Teva's Adderall 30 mg Tablets: Counterfeit Product - Contains Wrong Active Ingredients
ISSUE: FDA is warning consumers and health care professionals about a counterfeit version of Teva Pharmaceutical Industries' Adderall 30 milligram tablets that is being purchased on the Internet....
Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
PHILADELPHIA, February 7, 2012 /PRNewswire/ – Vyvanse (lisdexamfetamine dimesylate), an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the...
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
PHILADELPHIA - November 15, 2010 Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse...
Shionogi Announces FDA Approval of Kapvay - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
FLORHAM PARK, N.J., Oct. 4 /PRNewswire/ – Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the non-stimulant...
FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ – Shire plc , the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana...
Further information
Related condition support groups
Related drug support groups
Adderall, bupropion, Vyvanse, amphetamine, Adderall XR, Concerta, methamphetamine, Ritalin, Strattera, view more... clonidine, methylphenidate, modafinil, dextroamphetamine, amphetamine / dextroamphetamine, amantadine, guanfacine, 5-HTP, desvenlafaxine, Focalin, Focalin XR